A detailed history of State Of Wyoming transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, State Of Wyoming holds 3,058 shares of SUPN stock, worth $108,864. This represents 0.01% of its overall portfolio holdings.

Number of Shares
3,058
Previous 2,793 9.49%
Holding current value
$108,864
Previous $74,000 28.38%
% of portfolio
0.01%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$25.77 - $35.16 $6,829 - $9,317
265 Added 9.49%
3,058 $95,000
Q2 2024

Aug 14, 2024

BUY
$25.99 - $33.85 $8,030 - $10,459
309 Added 12.44%
2,793 $74,000
Q1 2024

May 13, 2024

SELL
$27.11 - $35.17 $4,364 - $5,662
-161 Reduced 6.09%
2,484 $84,000
Q4 2023

Feb 14, 2024

SELL
$22.72 - $29.68 $17,994 - $23,506
-792 Reduced 23.04%
2,645 $76,000
Q3 2023

Nov 14, 2023

SELL
$27.57 - $32.91 $69,228 - $82,637
-2,511 Reduced 42.22%
3,437 $94,000
Q2 2023

Aug 14, 2023

BUY
$29.91 - $38.73 $658 - $852
22 Added 0.37%
5,948 $178,000
Q1 2023

May 12, 2023

SELL
$34.93 - $42.03 $13,797 - $16,601
-395 Reduced 6.25%
5,926 $214,000
Q4 2022

Feb 14, 2023

BUY
$31.09 - $37.88 $79,870 - $97,313
2,569 Added 68.47%
6,321 $225,000
Q3 2022

Nov 14, 2022

SELL
$28.79 - $35.41 $45,344 - $55,770
-1,575 Reduced 29.57%
3,752 $127,000
Q2 2022

Aug 15, 2022

BUY
$25.33 - $34.25 $48,912 - $66,136
1,931 Added 56.86%
5,327 $154,000
Q1 2022

May 13, 2022

BUY
$28.51 - $32.9 $35,951 - $41,486
1,261 Added 59.06%
3,396 $110,000
Q4 2021

Feb 11, 2022

SELL
$26.37 - $34.22 $1,661 - $2,155
-63 Reduced 2.87%
2,135 $62,000
Q3 2021

Feb 11, 2022

BUY
$23.54 - $31.39 $8,615 - $11,488
366 Added 19.98%
2,198 $59,000
Q2 2021

Feb 11, 2022

BUY
$26.72 - $33.19 $48,951 - $60,804
1,832 New
1,832 $56,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.9B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track State Of Wyoming Portfolio

Follow State Of Wyoming and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Of Wyoming, based on Form 13F filings with the SEC.

News

Stay updated on State Of Wyoming with notifications on news.